1-6 of 6
Jay Harper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D’Angelo, Andrew Garcia, Hong Chen, Allison M. Barrett, Sandrina Phipps, Ryan Fleming, Sonja Hess, Jens-Oliver Koopmann, Nazzareno Dimasi, Susan Wilson, Kathryn Pugh, Kimberly Cook, Luke A. Masterson, Changshou Gao, Herren Wu, Ronald Herbst, Philip W. Howard, David A. Tice, Mark Cobbold, Jay Harper
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (3): 541–552.
https://doi.org/10.1158/1535-7163.MCT-20-0351
Published: 02 March 2021
View article titled, Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Open the PDF for Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR in another window
Includes: Supplementary data
Journal Articles

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition

Haihong Zhong, Cui Chen, Ravinder Tammali, Shannon Breen, Jing Zhang, Christine Fazenbaker, Maureen Kennedy, James Conway, Brandon W. Higgs, Nicholas Holoweckyj, Rajiv Raja, Jay Harper, Andrew J. Pierce, Ronald Herbst, David A. Tice
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (1): 89–99.
https://doi.org/10.1158/1535-7163.MCT-18-0314
Published: 02 January 2019
View article titled, Improved Therapeutic Window in <em>BRCA</em>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
Open the PDF for Improved Therapeutic Window in <em>BRCA</em>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4

Jay Harper, Christopher Lloyd, Nazzareno Dimasi, Dorin Toader, Rose Marwood, Leeanne Lewis, David Bannister, Jelena Jovanovic, Ryan Fleming, Francois D'Hooge, Shenlan Mao, Allison M. Marrero, Martin Korade, III, Patrick Strout, Linda Xu, Cui Chen, Leslie Wetzel, Shannon Breen, Lilian van Vlerken-Ysla, Sanjoo Jalla, Marlon Rebelatto, Haihong Zhong, Elaine M. Hurt, Mary Jane Hinrichs, Keven Huang, Philip W. Howard, David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Adeela Kamal
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (8): 1576–1587.
https://doi.org/10.1158/1535-7163.MCT-16-0825
Published: 02 August 2017
View article titled, Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Open the PDF for Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 in another window
Includes: Supplementary data
Journal Articles

Abstract B170: Discovery of tubulysin payloads for antibody drug conjugates with potent in vitro activity and in vivo efficacy in solid tumor models

Dorin Toader, Jay Harper, Chris Lloyd, Rose Marwood, David Bannister, Shenlan Mao, Cui (Tracy) Chen, Haihon (Helen) Zhong, Vahe Bedian, Fengjiang Wang, Lakshmaiah Gingipalli, Melisa Vasbinder, Pamela Thompson, Ryan Fleming, Byniam Bezabeh, Nazzareno Dimasi, Changshou Gao, Adeela Kamal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B170.
https://doi.org/10.1158/1535-7163.TARG-15-B170
Published: 01 December 2015
View article titled, Abstract B170: Discovery of tubulysin payloads for antibody drug conjugates with potent <em>in vitro</em> activity and <em>in vivo</em> efficacy in solid tumor models
Journal Articles

Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies

Cecile Rouleau, Diego A. Gianolio, Robert Smale, Stephanie D. Roth, Roy Krumbholz, Jay Harper, Kenneth J. Munroe, Tessa L. Green, Bruce C. Horten, Steven M. Schmid, Beverly A. Teicher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (9): 2081–2089.
https://doi.org/10.1158/1535-7163.MCT-15-0312
Published: 02 September 2015
View article titled, Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies
Open the PDF for Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies in another window
Includes: Supplementary data
Journal Articles

Abstract B244: Inhibition of metastases by a neutralizing TGFβ‐specific antibody involves the activity of cytotoxic T lymphocytes and natural killer cells

Kenneth Munroe, Charlene Manning, Tessa Green, Jingzang Tao, Kailene Simon, John McPherson, Johanne Kaplan, Jan Pinkas, Megan O'Brien, Richard Gregory, Jay Harper, Scott Lonning
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B244.
https://doi.org/10.1158/1535-7163.TARG-09-B244
Published: 10 December 2009
View article titled, Abstract B244: Inhibition of metastases by a neutralizing TGFβ‐specific antibody involves the activity of cytotoxic T lymphocytes and natural killer cells